Key statistics
As of last trade Amarin Corporation PLC (AMRN:NMQ) traded at 0.5758, 1.91% above its 52-week low of 0.565, set on Sep 24, 2024.
52-week range
Open | 0.5761 |
---|---|
High | 0.590 |
Low | 0.57 |
Bid | 0.5701 |
Offer | 0.5758 |
Previous close | 0.5762 |
Average volume | 882.18k |
---|---|
Shares outstanding | 410.87m |
Free float | 381.00m |
P/E (TTM) | -- |
Market cap | 236.74m USD |
EPS (TTM) | -0.082 USD |
Data delayed at least 15 minutes, as of Oct 08 2024 17:30 BST.
More ▼
- Amarin Announces Two Upcoming Investor Events
- Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual European Association for the Study of Diabetes (EASD) Meeting
- Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress
- Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal
- Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024
- Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR)
- Amarin Board of Directors Announces CEO Transition
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A.
- Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference
More ▼